Clinical Trials › NCT07225504
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 1275
Target enrollment
10
U.S. states
Nov 2025
Start date
Jan 2034
Expected completion
Interventions / Treatments
Remibrutinib (blinded)PlaceboRemibrutinib (Open label)
Conditions studied
Secondary Progressive Multiple Sclerosis (SPMS)
Where this trial is running (16 sites)
Participating MS centers on MS Buddy (10)
Center for Neurosciences
Tucson, AZ
Tucson, AZ
Michigan Institute For Neurological Disorders MIND
Farmington Hills, MI
Farmington Hills, MI
Regina Berkovich MD PhD Inc MS Neurology
West Hollywood, CA
West Hollywood, CA
Neurology of Central Florida
Altamonte Springs, FL
Altamonte Springs, FL
Tanner Center for Multiple Sclerosis
Birmingham, AL
Birmingham, AL
Neurology Associates of Ormond Beach
Ormond Beach, FL
Ormond Beach, FL
Neurology Clinic PC
Cordova, TN
Cordova, TN
AZ Integrated Neuro and Spine MS Center
Phoenix, AZ
Phoenix, AZ
Fullerton Neurology and Headache Center
Fullerton, CA
Fullerton, CA
MS centers in Florida
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Florida centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
